| Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K JM Munck, MA Batey, Y Zhao, H Jenkins, CJ Richardson, C Cano, ... Molecular cancer therapeutics 11 (8), 1789-1798, 2012 | 146 | 2012 |
| DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia E Willmore, SL Elliott, T Mainou-Fowler, GP Summerfield, GH Jackson, ... Clinical cancer research 14 (12), 3984-3992, 2008 | 134 | 2008 |
| Identification and Characterization of an Irreversible Inhibitor of CDK2 E Anscombe, E Meschini, R Mora-Vidal, MP Martin, D Staunton, ... Chemistry & biology 22 (9), 1159-1164, 2015 | 114 | 2015 |
| Synthetic cannabinoid receptor agonists: classification and nomenclature AJ Potts, C Cano, SHL Thomas, SL Hill Clinical Toxicology 58 (2), 82-98, 2020 | 109 | 2020 |
| Cyclin-dependent kinase (CDK) inhibitors: structure–activity relationships and insights into the CDK-2 selectivity of 6-substituted 2-arylaminopurines CR Coxon, E Anscombe, SJ Harnor, MP Martin, B Carbain, BT Golding, ... Journal of medicinal chemistry 60 (5), 1746-1767, 2017 | 107 | 2017 |
| Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure− activity relationships for DNA-dependent protein kinase inhibition … JJ Hollick, LJM Rigoreau, C Cano-Soumillac, X Cockcroft, NJ Curtin, ... Journal of medicinal chemistry 50 (8), 1958-1972, 2007 | 99 | 2007 |
| FragLites—minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation DJ Wood, JD Lopez-Fernandez, LE Knight, I Al-Khawaldeh, C Gai, S Lin, ... Journal of Medicinal Chemistry 62 (7), 3741-3752, 2019 | 86 | 2019 |
| Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination M Tavecchio, JM Munck, C Cano, DR Newell, NJ Curtin Cancer chemotherapy and pharmacology 69, 155-164, 2012 | 82 | 2012 |
| Targeting DNA‐dependent protein kinase for cancer therapy SJ Harnor, A Brennan, C Cano ChemMedChem 12 (12), 895-900, 2017 | 77 | 2017 |
| Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy CE Willoughby, Y Jiang, HD Thomas, E Willmore, S Kyle, A Wittner, ... The Journal of clinical investigation 130 (1), 258-271, 2020 | 64 | 2020 |
| DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype C Cano, OR Barbeau, C Bailey, XL Cockcroft, NJ Curtin, H Duggan, ... Journal of medicinal chemistry 53 (24), 8498-8507, 2010 | 58 | 2010 |
| Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer G Beale, EJ Haagensen, HD Thomas, LZ Wang, CH Revill, SL Payne, ... British journal of cancer 115 (6), 682-690, 2016 | 57 | 2016 |
| 1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK/PI3-K Inhibitory Activity C Cano, K Saravanan, C Bailey, J Bardos, NJ Curtin, M Frigerio, ... Journal of medicinal chemistry 56 (16), 6386-6401, 2013 | 54 | 2013 |
| Recent advances in CDK inhibitors for cancer therapy AB Heptinstall, IWS Adiyasa, C Cano, IR Hardcastle Future Medicinal Chemistry 10 (11), 1369-1388, 2018 | 51 | 2018 |
| Trifluoroacetic Acid in 2,2,2‐Trifluoroethanol Facilitates SNAr Reactions of Heterocycles with Arylamines B Carbain, CR Coxon, H Lebraud, KJ Elliott, CJ Matheson, E Meschini, ... Chemistry–A European Journal 20 (8), 2311-2317, 2014 | 42 | 2014 |
| Structure-based design of potent and orally active isoindolinone inhibitors of MDM2-p53 protein–protein interaction G Chessari, IR Hardcastle, JS Ahn, B Anil, E Anscombe, RH Bawn, ... Journal of Medicinal Chemistry 64 (7), 4071-4088, 2021 | 37 | 2021 |
| Quinolinone and pyridopyrimidinone inhibitors of DNA-dependent protein kinase OR Barbeau, C Cano-Soumillac, RJ Griffin, IR Hardcastle, GCM Smith, ... Organic & Biomolecular Chemistry 5 (16), 2670-2677, 2007 | 37 | 2007 |
| Synthesis and biological evaluation of 5-substituted O 4-alkylpyrimidines as CDK2 inhibitors F Marchetti, C Cano, NJ Curtin, BT Golding, RJ Griffin, K Haggerty, ... Organic & biomolecular chemistry 8 (10), 2397-2407, 2010 | 36 | 2010 |
| Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives KM Clapham, T Rennison, G Jones, F Craven, J Bardos, BT Golding, ... Organic & biomolecular chemistry 10 (33), 6747-6757, 2012 | 35 | 2012 |
| 8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) M Desage-El Murr, C Cano, BT Golding, IR Hardcastle, M Hummersome, ... Bioorganic & medicinal chemistry letters 18 (17), 4885-4890, 2008 | 35 | 2008 |
